Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K8 | P41279 | 5/20 | 0.64 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | CDK8 | P49336 | 2/20 | 0.47 |
| ▸ | CCNC | P24863 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 7/20 | 0.45 |
| ▸ | PIM1 | P11309 | 2/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.45 |
| ▸ | PRKACA | P17612 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.45 |
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5553889 | 0.88 | MAP3K8 (0.65) | MAP3K8MAP2K1MAPK1CDK8CSF1R | |
| SCHEMBL5553787 | 0.88 | MAP3K8 (0.65) | MAP3K8MAP2K1MAPK1CDK8CCNC | |
| SCHEMBL5550658 | 0.87 | MAP3K8 (0.64) | MAP3K8MAP2K1MAPK1CDK8CCNC | |
| SCHEMBL5554216 | 0.82 | MAP3K8 (0.60) | MAP3K8MAP2K1MAPK1CDK8CSF1R | |
| SCHEMBL5550360 | 0.81 | MAP3K8 (0.57) | MAP3K8MAP2K1MAPK1CDK8CSF1R | |
| SCHEMBL5550172 | 0.78 | MAP3K8 (0.53) | MAP3K8MAP2K1MAPK1CDK8CSF1R | |
| SCHEMBL5550743 | 0.78 | MAP3K8 (1.00) | MAP3K8MAP2K1MAPK1CDK8CCNC | |
| SCHEMBL5550740 | 0.77 | MAP3K8 (0.63) | MAP3K8MAP2K1MAPK1CDK8CCNC | |
| SCHEMBL5550805 | 0.76 | MAP3K8 (0.53) | MAP3K8CDK8CCNCGSK3AGSK3B | |
| SCHEMBL5555801 | 0.75 | MAP3K8 (0.59) | MAP3K8MAP2K1MAPK1CDK8CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753428-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | Abbott Laboratories (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABBOTT LABORATORIES | 2006-04-06 | — | — | US | disclosed |
| WO-2005110410-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABL1, MAP3K19, MAP3K20 | MAP3K8 13/4885MAP2K1 216/4885MAPK1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.